Creation of the Biobank Related to Eye Disease (BioBank)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Vision Research Foundation
Information provided by (Responsible Party):
Kimberly Drenser, William Beaumont Hospitals
ClinicalTrials.gov Identifier:
NCT01240343
First received: November 10, 2010
Last updated: February 1, 2016
Last verified: February 2016
  Purpose
The purpose of this study is to develop a BioBank (a specialized lab) and collect blood, fluids and/or other tissue samples to study eye diseases.

Condition
Eye Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Creation of the Biobank Related to Eye Disease

Resource links provided by NLM:


Further study details as provided by William Beaumont Hospitals:

Primary Outcome Measures:
  • To build the platform for a novel application of translational research that links cutting edge molecular laboratory techniques to clinical outcome studies [ Time Frame: unknown ] [ Designated as safety issue: No ]
    Biobanks can be used for numberous discovery applications such as: identification and structural characterization of human genes, expression analysis, or discovery proteomics. Biological specimens, when coupled with standardized treatment and outcome data, will be essential resources for the identification, characterization and validation of biomarkers that are predictive of disease and treatment.


Biospecimen Retention:   Samples With DNA
blood, urine other body fluids (i.e. vitreous)

Estimated Enrollment: 2000
Study Start Date: June 2009
Estimated Study Completion Date: June 2024
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of the Biobank related to eye disease at Beaumont Hospital is to help connect specialties and Specialists with each other, outside traditional limits of hospital or laboratory departments. The specimens (blood, fluids, and/or tissue samples) that will be collected from men, women and children will assist the researchers in a variety of studies on human eye diseases.

Research utilizing these specimens will allow for an increased understanding of the etiology, disease process, and response to treatments for various eye diseases, and will provide opportunities to subsequently improve our management decisions. Furthermore, projects that cross over between subspecialties are sparse and that is a limiting factor for the development of research that takes a more comprehensive approach.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All pediatric and adult patients (age 0-99)who are being seen in the eye Dr. office and or having eye surgery
Criteria

Inclusion Criteria: All pediatric and adult patients age 0-99 years -

Exclusion Criteria: All patients who do not agree to consent for collection of blood, fluids, tissue.

Patients who are cognitively impaired and are not able to verbalize understanding of the risks/benefits.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01240343

Locations
United States, Michigan
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
Sponsors and Collaborators
Kimberly Drenser
Vision Research Foundation
Investigators
Principal Investigator: Kimberly Drenser, MD, PhD Associated Retinal Consultants, P.C.
  More Information

Responsible Party: Kimberly Drenser, M.D, Ph.D., William Beaumont Hospitals
ClinicalTrials.gov Identifier: NCT01240343     History of Changes
Other Study ID Numbers: 2009-057 
Study First Received: November 10, 2010
Last Updated: February 1, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by William Beaumont Hospitals:
Biobank
Genetics

Additional relevant MeSH terms:
Eye Diseases

ClinicalTrials.gov processed this record on August 30, 2016